These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 8608877

  • 1. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
    Modigliani R, Colombel JF, Dupas JL, Dapoigny M, Costil V, Veyrac M, Duclos B, Soulé JC, Gendre JP, Galmiche JP, Danne O, Cadiot G, Lamouliatte H, Belaïche J, Mary JY.
    Gastroenterology; 1996 Mar; 110(3):688-93. PubMed ID: 8608877
    [Abstract] [Full Text] [Related]

  • 2. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Gendre JP, Mary JY, Florent C, Modigliani R, Colombel JF, Soulé JC, Galmiche JP, Lerebours E, Descos L, Viteau JM.
    Gastroenterology; 1993 Feb; 104(2):435-9. PubMed ID: 8425685
    [Abstract] [Full Text] [Related]

  • 3. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Florent C, Cortot A, Quandale P, Sahmound T, Modigliani R, Sarfaty E, Valleur P, Dupas JL, Daurat M, Faucheron JL, Lerebours E, Michot F, Belaiche J, Jacquet N, Soulé JC, Rothman N, Gendre JP, Malafosse M.
    Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):229-33. PubMed ID: 8724022
    [Abstract] [Full Text] [Related]

  • 4. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives.
    Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, Bories P, See A, Metman EH, Florent C.
    Gastroenterology; 1992 May; 102(5):1647-53. PubMed ID: 1568574
    [Abstract] [Full Text] [Related]

  • 5. Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
    Lerebours E, Bussel A, Modigliani R, Bastit D, Florent C, Rabian C, René E, Soulé JC.
    Gastroenterology; 1994 Aug; 107(2):357-61. PubMed ID: 8039612
    [Abstract] [Full Text] [Related]

  • 6. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group.
    Sutherland LR, Martin F, Bailey RJ, Fedorak RN, Poleski M, Dallaire C, Rossman R, Saibil F, Lariviere L.
    Gastroenterology; 1997 Apr; 112(4):1069-77. PubMed ID: 9097988
    [Abstract] [Full Text] [Related]

  • 7. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Colombel JF, Lémann M, Cassagnou M, Bouhnik Y, Duclos B, Dupas JL, Notteghem B, Mary JY.
    Am J Gastroenterol; 1999 Mar; 94(3):674-8. PubMed ID: 10086650
    [Abstract] [Full Text] [Related]

  • 8. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR, Mays DA.
    Ann Pharmacother; 1997 Mar; 31(7-8):907-13. PubMed ID: 9220055
    [Abstract] [Full Text] [Related]

  • 9. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
    Mantzaris GJ, Petraki K, Sfakianakis M, Archavlis E, Christidou A, Chadio-Iordanides H, Triadaphyllou G.
    Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
    [Abstract] [Full Text] [Related]

  • 10. [Maintenance treatment of Crohn's disease using orally administered mesalazine (Pentasa). A controlled multicenter study. The Study Groups on the Treatment of Inflammatory Digestive Disorders].
    Gendre JP, Mary JY, Florent C, Modigliani R, Colombel JF, Soulé JC, Galmiche JP, Lerebours E, Descos L, Viteau JM.
    Ann Gastroenterol Hepatol (Paris); 1993 Oct; 29(5):251-6. PubMed ID: 8250520
    [Abstract] [Full Text] [Related]

  • 11. A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission.
    Arber N, Odes HS, Fireman Z, Lavie A, Broide E, Bujanover Y, Becker S, Pomerantz I, Moshkowitz M, Patz J.
    J Clin Gastroenterol; 1995 Apr; 20(3):203-6. PubMed ID: 7797827
    [Abstract] [Full Text] [Related]

  • 12. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.
    Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, Petritsch W, Raithel M, Hoffmann R, Gross V, Plauth M, Staun M, Nesje LB.
    Gastroenterology; 2000 Feb; 118(2):264-73. PubMed ID: 10648454
    [Abstract] [Full Text] [Related]

  • 13. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
    Thomson AB, Wright JP, Vatn M, Bailey RJ, Rachmilewitz D, Adler M, Wilson-Lynch KA.
    Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
    [Abstract] [Full Text] [Related]

  • 14. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group.
    Gross V, Andus T, Ecker KW, Raedler A, Loeschke K, Plauth M, Rasenack J, Weber A, Gierend M, Ewe K, Schölmerich J.
    Gut; 1998 Apr; 42(4):493-6. PubMed ID: 9616309
    [Abstract] [Full Text] [Related]

  • 15. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
    Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, Krawitt EL.
    Gastroenterology; 1993 May; 104(5):1293-301. PubMed ID: 8482443
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
    Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, Vatn M, Persson T, Pettersson E.
    N Engl J Med; 1998 Aug 06; 339(6):370-4. PubMed ID: 9691103
    [Abstract] [Full Text] [Related]

  • 19. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group.
    Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA.
    Am J Gastroenterol; 1993 Sep 06; 88(9):1343-51. PubMed ID: 8362827
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis.
    Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR.
    J Clin Gastroenterol; 1994 Dec 06; 19(4):278-82. PubMed ID: 7876505
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.